Answers are grounded in this paper and cite their sources.
Treatment of late ABMR with steroids/IVIG ± rituximab was effective in reducing DSA and microcirculation inflammation. The addition of rituximab was associated with better graft survival. Follow-up biopsies could be considered in the management of acute rejection to monitor the effect of therapy. Randomized studies on the best therapeutic options for ABMR are needed.
No takes yet. Share an insight, caveat, or question.
Parajuli et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: